Strategic leaks of "comparable companies" to media outlets are a key tool for stealth startups to signal their direction. Analysts can reverse-engineer a company's strategy, target market, and talent focus by scrutinizing these chosen comps. This turns PR into a powerful source of competitive intelligence.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Vivtex's early low profile was a strategic choice to mature its technology and precisely define its value to partners. This 'figuring it out' period allowed them to avoid making a premature public splash with offerings they might later have to retract, ensuring a stronger, more coherent market entry.

Vivtex used stealth mode not for secrecy, but to give itself a 'time window' to fully develop its technology and nail down its precise application. This prevented them from making public promises they might later have to retract, ensuring a more stable and confident market entry.

For seven years, Travis Kalanick's new venture operated in extreme secrecy. Thousands of employees listed "Stealth" on LinkedIn, and the company used different, generic names in each of its 30 countries. This strategy concealed its scale and mission from competitors while building an intense internal culture.

Beren Therapeutics stayed in stealth not just for competitive reasons, but to mend relationships with a patient community fatigued by previous sponsors' failures. This private, focused engagement allowed them to earn trust and protect employees before facing public scrutiny, a strategic use of stealth for community relations.

BGV's massive success, Assertifarma, originated from a Merck reorganization. The founding team, who were being let go, identified a shelved drug intended for inflammation and repurposed it for leukemia, negotiating the license amidst the corporate shuffle. This highlights the hidden opportunities within large pharma portfolios.

To achieve a high-value acquisition, biotechs must first build a credible strategy to succeed independently, creating a position of strength. Concurrently, leaders should keep multiple potential suitors proactively informed on all business aspects—not just clinical data—to facilitate a competitive bidding process when the time comes.

Assertifarma's pivotal US team, with crucial experience on a competitor's drug, was found by chance. BGV's founder was pitched by them at a conference but flipped the script and recruited them for his own project, proving the power of opportunistic networking and recognizing expertise on the fly.